Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

NCT00801125 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00801125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00801125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Withdrawn
Start date
December 31, 2008
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease